Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
Sax, that's a good point actually. Faron can't currently issue in the US but a self issue would enable Faron to sell its shares to a US entity or to any other investor or partner for that matter. With the market the way it is currently, especially in the US, this could be a shrewd move by Markku.
It doesn't really matter whether an issuer self-issues for a sale to a third party or issues directly to a third party. The effect is dilution - in this case up to 20%. At least this should be an opportunity to buy lower for those who believe in Faron.
I have been bullish (and also in profit) for the best part of two years but at some stage the head has to have priority over the heart and I have decided to sell a good part of my holding. I was hoping that the flatlining of the share price recently meant that something big was going on in the background, and the SP could have broken up or down. Unfortunately it was down and has continued in that direction. I have however retained a few shares just in case the SSV ever materialises.
I don't really believe that the size and number of trades have a direct impact on the SP of Faron or any of the other shares on AIM for that matter. The SP is whatever the MMs want it to be absent significant news whether it be good or bad. I'm quite happy for the SP to drift for a while as it will provide another buying opportunity.
There have been quite a few reports of buys being shown as sells and I have just done a small top up (1000) which has also been shown as a sell. A lot of the larger sells over the last couple of days could easily have been buys. Those who have been in Faron for a while are used to these sort of mm games.
Rick, I have been a shareholder in Faron for a couple of years and invested in SNG a year or so ago due to the similarity in formulation with Traumakine. The big difference though is that it is administered in nebuliser form and is intended for home use on the early onset of Covid so does not have the same problem with steroids as Traumakine which, because of its application by IV, will usually take place in hospital where the patient may be on steroids. I am still hopeful though for Traumakine if not for Covid then for ARDS.
CWebb, on this occasion I think you can blame the MMs. There were only two sells of significance totalling 3500 shares and the SP dropped 50 points and it went back up 20 points without any more trades. The MMs were clearly trying to catch people out but it didn't work. The 50 point drop didn't trigger any stops because people are holding on to their shares for dear life. They know that good news is around the corner.
I read the other day that MMs can actually see what stop losses exist on their shares. I don't know if this is true or not but even if it isn't it is pretty easy to work out what stop losses buyers will have set. It is like shooting fish in a barrel for a MM to take out stops.
I have been thinking t/o recently. The discussions with partners have been going on so long that it makes you wonder if something else is going on, especially given the acquisitions experience of John Poulos who was appointed to the board a couple of years ago.
As a shareholder I would like to know what is going on but I do understand Faron's position here. While a drug is in trials, they cannot really say anything, other than trials are ongoing (which would of course be pointless), until the trials are concluded or a certain phase has been reached. An RNS saying eg that trials are going well would send the market crazy and would be market manipulation of the highest order. When the time is right and Faron is legally able to say something by way of an RNS, they will. Although waiting is not easy and I am as nervous as anyone else, while there is no news Faron is still in the game and riches are a distinct possibility.